journal article·2025-04-08Open access

2-Nitroimidazole-Functionalized Superparamagnetic Iron Oxide Nanoparticles Detect Hypoxic Regions of Glioblastomas on MRI and Improve Radiotherapy Efficacy

Yuki Yoshino, Fumi Yoshino, Ichio Aoki, Yasuyuki Mori, Gen Suzuki, Shunichiro Tsuji, Tsukuru Amano, Akihiko Shiino, Tokuhiro Chano, Yoshio Furusho, Takashi Murakami, Hideya Yamazaki, Kei Yamada

ACS Nano· Volume 19· Issue 13

Abstract

High Resolution Image Download MS PowerPoint Slide The presence of hypoxic regions in tumors is associated with malignancy and is an important target for the high-precision diagnosis and treatment of tumors. Radioresistant hypoxic regions can be precisely identified and treated without the use of high doses of radiation if hypoxic region-specific contrast agents have a therapeutic effect. In this study, we synthesized a therapeutic-diagnostic complex agent (SPION-PG-NI) by combining polyglycerol-functionalized superparamagnetic iron oxide nanoparticles (SPION-PG, core diameter of 8.8 ± 1.9 nm) as an MRI contrast agent and 2-nitroimidazole (NI, a pimonidazole derivative) as a hypoxia-targeted ligand to visually evaluate hypoxic regions using MRI and improve radiotherapy efficacy at those sites. SPION-PG-NI showed a concentration-dependent contrast effect and had significantly higher accumulation in subcutaneous glioblastomas than the control agent, SPION-PG, 24 h after administration. Immunohistological evaluations showed that the SPION-PG-NI-accumulated regions corresponded well to hypoxic regions. SPION-PG-NI showed neither migration into the brain parenchyma nor neurotoxicity. Both SPION-PG and SPION-PG-NI decrease reactive oxygen species (ROS); however, they improve radiotherapy efficacy in hypoxic glioblastoma cells due to cytotoxicity. This effect of SPION-PG-NI was significantly higher than that of SPION-PG ( p < 0.01). After 12 Gy irradiation, the mean normalized glioblastoma tumor volume on day 38 in the SPION-PG-NI group (288%) was significantly lower than that in the control group (882%) ( p < 0.05). Collectively, these findings suggest the potential of SPION-PG-NI as a useful and safe tumor theranostic nanodevice for hypoxic imaging and improving radiotherapy efficacy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan

Kansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakucho, Takatsuki Osaka 569-8686, Japan

Department of Obstetrics and Gynecology, Shiga University of Medical Science, Seta, Otsu 520-2192, Japan

Mariko Clinic, 13-5 Noji, Kusatsu 525-0059, Japan

Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Anagawa 4-9-1, Inage 263-8555 Chiba, Japan

Department of Chemistry

Shiga University of Medical Science

Department of Molecular Neuroscience Research Center

Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Seta, Otsu 520-2192, Japan

Funding

Japan Society for the Promotion of Science

References (60)

Show source-provided references
1. 10.1016/S1535-6108(03)00085-010.1016/S1535-6108(03)00085-0 ↗
2. 10.1038/bjc.1955.5510.1038/bjc.1955.55 ↗
3. 10.1016/0360-3016(94)90432-410.1016/0360-3016(94)90432-4 ↗
4. 10.1038/nrclinonc.2012.17110.1038/nrclinonc.2012.171 ↗
5. 10.1016/j.redox.2018.10108410.1016/j.redox.2018.101084 ↗
6. 10.1126/science.121148510.1126/science.1211485 ↗
7. 10.2307/357855610.2307/3578556 ↗
8. 10.2967/jnumed.107.04591410.2967/jnumed.107.045914 ↗
9. 10.1371/journal.pone.016163910.1371/journal.pone.0161639 ↗
10. 10.1007/BF0136759510.1007/BF01367595 ↗
11. 10.1007/s40336-017-0238-710.1007/s40336-017-0238-7 ↗
12. 10.1158/0008-5472.CAN-20-095010.1158/0008-5472.CAN-20-0950 ↗
13. 10.1002/mrm.2482610.1002/mrm.24826 ↗
14. 10.1038/nnano.2016.7210.1038/nnano.2016.72 ↗
15. 10.1021/acsanm.2c0385010.1021/acsanm.2c03850 ↗
16. 10.1021/jacs.0c1024510.1021/jacs.0c10245 ↗
17. 10.1002/adfm.20190928510.1002/adfm.201909285 ↗
18. 10.3892/or.19.6.138910.3892/or.19.6.1389 ↗
19. 10.3390/ijms2014349610.3390/ijms20143496 ↗
20. 10.1259/bjr.2017091510.1259/bjr.20170915 ↗
21. 10.1016/j.addr.2015.01.00210.1016/j.addr.2015.01.002 ↗
22. 10.1016/j.bbcan.2016.06.00410.1016/j.bbcan.2016.06.004 ↗
23. 10.1016/j.biomaterials.2013.11.02210.1016/j.biomaterials.2013.11.022 ↗
24. 10.1056/NEJM19991223341260710.1056/NEJM199912233412607 ↗
25. 10.1148/radiology.218.1.r01ja242710.1148/radiology.218.1.r01ja2427 ↗
26. 10.1021/cm100566v10.1021/cm100566v ↗
27. 10.1002/adfm.20130429810.1002/adfm.201304298 ↗
28. 10.1016/j.biomaterials.2014.03.04110.1016/j.biomaterials.2014.03.041 ↗
29. 10.1002/adfm.20120106010.1002/adfm.201201060 ↗
30. 10.1021/acsami.9b0364010.1021/acsami.9b03640 ↗
31. 10.1021/acsnano.0c0401010.1021/acsnano.0c04010 ↗
32. 10.1002/adfm.20210996010.1002/adfm.202109960 ↗
33. 10.1097/01.rli.0000184756.66360.d310.1097/01.rli.0000184756.66360.d3 ↗
34. 10.1002/anie.20050224510.1002/anie.200502245 ↗
35. 10.1002/smll.20200346810.1002/smll.202003468 ↗
36. 10.1006/gyno.1998.516310.1006/gyno.1998.5163 ↗
37. 10.1038/nrc109310.1038/nrc1093 ↗
38. 10.1016/j.jconrel.2017.08.00310.1016/j.jconrel.2017.08.003 ↗
39. 10.7150/thno.3719810.7150/thno.37198 ↗
40. 10.18383/j.tom.2020.0004610.18383/j.tom.2020.00046 ↗
41. 10.1038/nnano.2017.17010.1038/nnano.2017.170 ↗
42. 10.1016/j.drup.2015.02.00210.1016/j.drup.2015.02.002 ↗
43. 10.1074/jbc.M20926420010.1074/jbc.M209264200 ↗
44. 10.1016/j.bbrc.2012.07.10810.1016/j.bbrc.2012.07.108 ↗
45. 10.1186/s13014-021-01829-y10.1186/s13014-021-01829-y ↗
46. 10.3389/fphar.2022.80647010.3389/fphar.2022.806470 ↗
47. 10.1016/j.redox.2022.10230010.1016/j.redox.2022.102300 ↗
48. 10.3109/1354750X.2012.71567210.3109/1354750X.2012.715672 ↗
49. 10.1042/BA2002005210.1042/BA20020052 ↗
50. 10.3390/s12091234710.3390/s120912347 ↗
51. 10.1007/s00018-020-03476-010.1007/s00018-020-03476-0 ↗
52. 10.1038/s12276-020-0384-210.1038/s12276-020-0384-2 ↗
53. 10.1016/S1382-6689(01)00118-110.1016/S1382-6689(01)00118-1 ↗
54. 10.1038/ncomms758210.1038/ncomms7582 ↗
55. 10.1038/s42003-020-01165-z10.1038/s42003-020-01165-z ↗
56. 10.1016/j.tips.2017.11.00310.1016/j.tips.2017.11.003 ↗
57. 10.7863/jum.2010.29.6.89110.7863/jum.2010.29.6.891 ↗
58. 10.3390/jpm1208124510.3390/jpm12081245 ↗
59. 10.1016/j.ijrobp.2007.08.03610.1016/j.ijrobp.2007.08.036 ↗
60. 10.7150/thno.1401810.7150/thno.14018 ↗